Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL67044 | 1.00 | HSD17B10 (0.69) | HSD17B10SMN1; SMN2RAB9ALMNACYP2C19 | |
| SCHEMBL27877016 | 1.00 | HSD17B10 (0.69) | HSD17B10SMN1; SMN2RAB9ALMNACYP2C19 | |
| SCHEMBL67045 | 1.00 | HSD17B10 (0.69) | HSD17B10SMN1; SMN2RAB9ALMNACYP2C19 | |
| SCHEMBL6219872 | 1.00 | HSD17B10 (0.69) | HSD17B10SMN1; SMN2RAB9ALMNACYP2C19 | |
| SCHEMBL20492528 | 0.98 | HSD17B10 (0.68) | HSD17B10SMN1; SMN2RAB9ALMNACYP2C19 | |
| Ammonia Solution, Strong SCHEMBL28264574 | 0.98 | HSD17B10 (0.68) | HSD17B10SMN1; SMN2RAB9ALMNACYP2C19 | |
| Hydrazine SCHEMBL28122430 | 0.97 | HSD17B10 (0.66) | HSD17B10SMN1; SMN2RAB9ALMNACYP2C19 | |
| SCHEMBL1809663 | 0.95 | HSD17B10 (0.64) | HSD17B10SMN1; SMN2RAB9ALMNACYP2C19 | |
| SCHEMBL77858 | 0.95 | HSD17B10 (0.63) | HSD17B10SMN1; SMN2RAB9ALMNACYP2C19 | |
| SCHEMBL65491 | 0.95 | HSD17B10 (0.63) | HSD17B10SMN1; SMN2RAB9ALMNACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1053 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024216095-A1 | SYNTHESIS OF MAVORIXAFOR AND INTERMEDIATES THEREOF | X4 PHARMACEUTICALS, INC. (US) | 2024-10-17 | — | — | WO | claimed |
| CN-112638871-B | (R) -4- (1- (1- (4- (trifluoromethyl) benzyl) pyrrolidine-2-carboxamide) cyclopropyl) benzoic acid as EP4 receptor antagonist | 罗达制药生物技术有限责任公司 | 2024-08-30 | — | — | CN | claimed |
| CN-116898921-B | Preparation method of cattail and dyer woad compound traditional Chinese medicine preparation | 江西新世纪民星动物保健品有限公司 | 2024-05-31 | — | — | CN | claimed |
| CN-117658830-A | Preparation method of trans-2-aminocyclopentanol with high optical purity | 大连双硼医药化工有限公司 | 2024-03-08 | — | — | CN | claimed |
| WO-2024017221-A1 | SYNTHESIS METHOD FOR α-AZIDO KETONE CONTAINING TERTIARY STEREOCENTER | 常州大学 | 2024-01-25 | — | — | WO | claimed |
| CN-114106050-B | Compact chiral environment biphenanthrene skeleton chiral phosphoric acid and preparation method and application thereof | 华东理工大学 | 2024-01-12 | — | — | CN | claimed |
| CN-116898921-A | Preparation method of cattail and dyer woad compound traditional Chinese medicine preparation | 江西新世纪民星动物保健品有限公司 | 2023-10-20 | — | — | CN | claimed |
| CN-115108937-B | Synthesis method of alpha-azido ketone containing three-level stereo center | 常州大学 | 2023-08-22 | — | — | CN | claimed |
| US-11718582-B2 | (R)-4-(1-(1-(4-(trifluoromethyl)benzyl)pyrrolidine-2-carboxamide)cyclopropyl)-benzoic acid as EP4 receptor antagonist | ROTTAPHARM BIOTECH S.R.L. (IT) | 2023-08-08 | — | — | US | claimed |
| CN-113773295-B | Synthesis method of monosubstituted dihydro chromone and application of monosubstituted dihydro chromone in treatment of pulmonary inflammation such as COPD (chronic disease) | 广东省科学院动物研究所 | 2023-06-20 | — | — | CN | claimed |
| EP-3820842-B1 | (R)-4-(1-(1-(4-(TRIFLUOROMETHYL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE)CYCLOPROPYL)-BENZOIC ACID AS EP4 RECEPTOR ANTAGONIST | Rottapharm Biotech Srl (IT) | 2023-03-29 | — | — | EP | claimed |
| CN-115108937-A | Synthesis method of alpha-azidoketone containing three-level stereocenter | 常州大学 | 2022-09-27 | — | — | CN | claimed |
| CN-114106050-A | Tight chiral environment biphenyl-phenanthrene framework chiral phosphoric acid and preparation method and application thereof | 华东理工大学 | 2022-03-01 | — | — | CN | claimed |
| EP-3820842-A1 | (R)-4-(1-(1-(4-(TRIFLUOROMETHYL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE)CYCLOPROPYL)-BENZOIC ACID AS EP4 RECEPTOR ANTAGONIST | Rottapharm Biotech S.r.l. (IT) | 2021-05-19 | — | — | EP | claimed |
| US-20210130290-A1 | (R)-4-(1-(1-(4-(TRIFLUOROMETHYL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE)CYCLOPROPYL)-BENZOIC ACID AS EP4 RECEPTOR ANTAGONIST | ROTTAPHARM BIOTECH S.R.L. (IT) | 2021-05-06 | — | — | US | claimed |
| CN-112638871-A | (R) -4- (1- (1- (4- (trifluoromethyl) benzyl) pyrrolidine-2-carboxamide) cyclopropyl) benzoic acid as EP4 receptor antagonists | 罗达制药生物技术有限责任公司 | 2021-04-09 | — | — | CN | claimed |
| WO-2020012305-A1 | (R)-4-(1-(1-(4-(TRIFLUOROMETHYL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE)CYCLOPROPYL)-BENZOIC ACID AS EP4 RECEPTOR ANTAGONIST | ROTTAPHARM BIOTECH S.R.L. (IT) | 2020-01-16 | — | — | WO | claimed |
| EP-4565562-B1 | PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | NXERA PHARMA UK LTD (GB) | 2026-05-27 | — | — | EP | disclosed |
| EP-0138407-A1 | Azetidinones | E.R. Squibb & Sons, Inc. (US) | 1985-04-24 | — | — | EP | disclosed |
| US-4505853-A | GLANDULAR DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1985-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718582-B2 | (R)-4-(1-(1-(4-(trifluoromethyl)benzyl)pyrrolidine-2-carboxamide)cyclopropyl)-benzoic acid as EP4 receptor antagonist | PTGER4, PTGER1, PTGER2 | HSD17B10 2486/4885SMN1; SMN2 3641/4885RAB9A 3772/4885 |
| US-20210130290-A1 | (R)-4-(1-(1-(4-(TRIFLUOROMETHYL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE)CYCLOPROPYL)-BENZOIC ACID AS EP4 RECEPTOR ANTAGONIST | PTGER4, PTGER1, PTGER2 | HSD17B10 2486/4885SMN1; SMN2 3641/4885RAB9A 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.